Insomnia is a disorder of impaired sleep initiation, duration, consolidation, or quality, occurring despite adequate opportunity and circumstances for sleep. A typical complaint is difficulty falling asleep, which aligns with the seed concept of “can’t sleep”. Clinically, insomnia is not defined by short sleep alone; it is defined by dissatisfaction with sleep and associated daytime impairment or distress, with symptoms persisting at least three nights per week for at least three months (for chronic insomnia). Acute insomnia can also occur, but the mechanistic discussion below applies broadly.
The prevailing framework for insomnia emphasizes hyperarousal: a state of increased physiological and cognitive activation that persists into the intended sleep period. Hyperarousal involves dysregulated autonomic nervous system activity (elevated sympathetic tone), altered hypothalamic-pituitary-adrenal axis functioning, and measurable changes in cortical excitability. At the cognitive level, insomnia often features conditioned arousal—where bed placement and bedtime cues trigger alertness rather than sleepiness—alongside worry, threat appraisal, and attentional bias toward internal sensations (e.g., monitoring heart rate, time-to-sleep, or perceived sleep depth).
Neurobiologically, insomnia has been associated with abnormalities across sleep-wake regulatory networks. Circadian rhythm disruption can shift melatonin secretion and sleep propensity, while homeostatic sleep pressure signaling may be impaired by irregular sleep timing, caffeine, nicotine, or other stimulants. Additionally, sleep architecture may show increased sleep fragmentation and reduced efficiency, with greater wake after sleep onset and altered REM/non-REM distribution. Importantly, insomnia is heterogeneous: some individuals predominantly have sleep-onset insomnia, others have maintenance insomnia, and many have mixed forms.
Common precipitating and perpetuating factors include stress, mood disorders (major depressive disorder, anxiety disorders), post-traumatic stress disorder, pain syndromes, restless legs syndrome, nocturia, gastroesophageal reflux, medication effects (e.g., corticosteroids, stimulants), and substance use. Behavioral contributors are often central: irregular schedules, spending excessive time in bed awake, napping late in the day, and inconsistent wake times. The cycle can be reinforced by cognitive factors such as catastrophic interpretation of poor sleep, which increases arousal and delays sleep further.
Assessment begins with a careful history and sleep diary, focusing on sleep timing, latency, awakenings, total sleep time, bed/wake consistency, daytime consequences, and screening for comorbidities. Clinicians should evaluate for medical causes (sleep apnea, periodic limb movements, endocrine disorders), substance-related insomnia, and medication-induced symptoms. Cognitive behavioral therapy for insomnia (CBT-I) is first-line for chronic insomnia and has strong evidence for sustained benefit. CBT-I targets perpetuating mechanisms through stimulus control (using the bed only for sleep/sex; exiting the bed when unable to sleep), sleep restriction therapy (consolidating time in bed to match actual sleep time, then gradually expanding), cognitive restructuring (reducing worry and performance pressure), and relaxation strategies.
Pharmacotherapy can be considered when symptoms are severe, when CBT-I is unavailable, or as short-term bridging. Medication choices depend on patient age, comorbidities, and risk profile. Hypnotics such as non-benzodiazepine benzodiazepine receptor agonists, melatonin receptor agonists, and certain low-dose sedating agents may be used selectively. However, long-term reliance on sedatives can lead to tolerance, dependence, adverse effects (falls, cognitive impairment), and rebound insomnia on discontinuation. Therefore, medication is typically limited in duration and paired with behavioral therapy when feasible.
Hygiene measures—while insufficient as standalone therapy—are supportive: maintaining consistent wake times, limiting caffeine after midday, reducing alcohol’s sleep-disrupting effects, and ensuring light exposure in the morning and darkness at night to support circadian alignment. For sleep-onset insomnia specifically, reducing bedtime time awake, avoiding late naps, and addressing conditioned arousal are particularly important.
When insomnia is chronic and intertwined with anxiety, the cognitive model suggests that worry scripts and threat monitoring sustain hyperarousal. In such cases, treating comorbid anxiety or depression improves sleep outcomes. If symptoms suggest sleep-disordered breathing (snoring with witnessed apneas, choking/gasping) or restless legs syndrome (urge to move legs, relief with movement), targeted evaluation and treatment are essential.
Ultimately, insomnia represents a biopsychosocial dysfunction of arousal regulation and circadian/homeostatic balance. A structured diagnostic workup plus CBT-I offers the highest probability of durable remission, while short-term medication may provide symptom relief. Source: [@Carpletto]
MarsHall: can’t sleep 😂😂😂😂 what a game. #breaking
— @Carpletto May 1, 2026
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
